Howard Pien is currently on leave of absence. Daniel Tassé acts as Interim Chair in Mr. Pien’s absence. Howard has worked in the pharmaceutical and biotechnology industries for over 30 years. Howard is currently an independent director of Idera Pharmaceuticals, Inc, a specialty pharmaceutical company listed on the NASDAQ Stock Market.
Howard was Non-Executive Chairman of Juno Therapeutics, a development stage company focused on immunotherapy aimed to cure cancer, until its acquisition by Celgene in 2018. He was also previously a director of Vanda, a commercial-stage public company specializing in CNS (three years as Chairman), ImmunoGen and an advisor to the Life Sciences Practice of Warburg Pincus. From 2007 to 2009, Howard was the Chairman and CEO of Medarex, Inc., a public biotechnology company, until it was acquired by Bristol-Myers Squibb. From 2003 to 2006, he was the Chairman and CEO of Chiron, a public biotechnology company, which was acquired by Novartis. His previous Board directorships include Talon, Arresto, Ikaria and Biopharma (where he was lead independent director) – all biopharmaceutical companies that were acquired in strategic transactions. Between 1991 and 2003, he held various executive positions at GlaxoSmithKline plc (GSK) and SmithKline Beecham, as Presidents of US, International, and Pharmaceuticals. Prior to GSK, Howard worked for Abbott Labs for six years and Merck & Co., Inc. for five years.
Howard’s past non-profit board appointments include the industry associations BIO and PhRMA, as well as Oakland Children’s Hospital and Fox Chase Hospital.
Howard graduated from MIT with a BS in engineering, and from Carnegie-Mellon University with an MBA.